Coeptis Therapeutics (COEP)

Executive Summary

Coeptis Therapeutics (NASDAQ: COEP) is a U.S.-based biopharmaceutical company developing innovative cell therapy platforms for cancer treatment. Its lead platform, SNAP-CAR, is a multi-antigen targeting system designed to improve the efficacy of CAR-T cell therapies, while its DARIC platform enables on-demand, allogeneic NK cell therapy. The company focuses on both hematologic malignancies and solid tumors, operating in preclinical and early clinical stages. As a publicly traded entity with a market capitalization of approximately $102 million, Coeptis faces significant competition but has potential value in advancing its novel platforms. The company's progress depends on successful preclinical and clinical data, regulatory milestones, and strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Data Release for SNAP-CAR Platform60% success
• Q1 2027IND Filing for DARIC NK Cell Therapy50% success
• Q3 2026Partnership or Licensing Agreement for SNAP-CAR40% success